High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as Biomarkers in Critically Ill COVID-19 Patients

Abstract. Exuberant inflammation manifesting as a “cytokine storm” has been suggested as a central feature in the pathogenesis of severe coronavirus disease 2019 (COVID-19). This study investigated two prognostic biomarkers, the high mobility group box 1 (HMGB1) and interleukin-6 (IL-6), in patients with severe COVID-19 at the time of admission in the intensive care unit (ICU). Of 60 ICU patients with COVID-19 enrolled and analyzed in this prospective cohort study, 48 patients (80%) were alive at ICU discharge. HMGB1 and IL-6 plasma levels at ICU admission were elevated compared with a healthy control, both in ICU nonsurvivors and ICU survivors. HMGB1 and IL-6 plasma levels were higher in patients with a higher Sequential Organ Failure Assessment (SOFA) score (> 10), and the presence of septic shock or acute kidney injury. HMGB1 and IL-6 plasma levels were also higher in patients with a poor oxygenation status (PaO2/FiO2 < 150 mm Hg) and a longer duration of ventilation (> 7 days). Plasma HMGB1 and IL-6 levels at ICU admission also correlated with other prognostic markers, including the maximum neutrophil/lymphocyte ratio, D-dimer levels, and C-reactive protein levels. Plasma HMGB1 and IL-6 levels at ICU admission predicted ICU mortality with comparable accuracy to the SOFA score and the COVID-GRAM risk score. Higher HMGB1 and IL-6 were not independently associated with ICU mortality after adjustment for age, gender, and comorbidities in multivariate analysis models. In conclusion, plasma HMGB1 and IL6 at ICU admission may serve as prognostic biomarkers in critically ill COVID-19 patients.

[1]  G. Criner,et al.  Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia , 2020, The New England journal of medicine.

[2]  Haichao Wang,et al.  HMGB1 as a potential biomarker and therapeutic target for severe COVID-19 , 2020, Heliyon.

[3]  C. Deutschman,et al.  Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes , 2020, The Lancet Respiratory Medicine.

[4]  Samuel M. Brown,et al.  Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study , 2020, The Lancet Rheumatology.

[5]  C. Wellington,et al.  Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome , 2020, European Respiratory Journal.

[6]  C. Wellington,et al.  The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019 , 2020, Critical care explorations.

[7]  W. Wang,et al.  Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[8]  J. Kellum,et al.  Endotoxemia and circulating bacteriome in severe COVID-19 patients , 2020, Intensive Care Medicine Experimental.

[9]  Feng-Zeng Li,et al.  Laboratory findings of COVID-19: a systematic review and meta-analysis , 2020, Scandinavian journal of clinical and laboratory investigation.

[10]  Zhenyu Li,et al.  The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.

[11]  Limin Ou,et al.  Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. , 2020, JAMA internal medicine.

[12]  K. Tracey,et al.  Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? , 2020, Molecular Medicine.

[13]  R. Assaly,et al.  Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis , 2020, Journal of medical virology.

[14]  Xuetao Cao.  COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[15]  E. Coomes,et al.  Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.

[16]  Qiu Zhao,et al.  Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Lei Liu,et al.  COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China , 2020, medRxiv.

[18]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[19]  B. Lipworth,et al.  Journal Pre-proof Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020 .

[20]  F. Biscetti,et al.  High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives , 2019, International journal of molecular sciences.

[21]  L. Mantell,et al.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases , 2019 .

[22]  A. Norrby-Teglund,et al.  High HMGB1 levels in sputum are related to pneumococcal bacteraemia but not to disease severity in community-acquired pneumonia , 2018, Scientific Reports.

[23]  F. Tacke,et al.  High mobility group box 1 as a biomarker in critically ill patients , 2018, Journal of clinical laboratory analysis.

[24]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[25]  V. Novack,et al.  Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. , 2015, American journal of respiratory and critical care medicine.

[26]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[27]  H. Tsukahara,et al.  Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice , 2015, Critical Care.

[28]  C. Fielding,et al.  Interleukin-6 in renal disease and therapy. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[30]  M. Fink.  HMGB1 as a drug target in staphylococcal pneumonia , 2014, Critical Care.

[31]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[32]  R. Star,et al.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1. , 2011, Kidney international.

[33]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[34]  Yang Liu,et al.  CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.

[35]  Haichao Wang,et al.  Therapeutic potential of HMGB1-targeting agents in sepsis , 2008, Expert Reviews in Molecular Medicine.

[36]  K. Tracey,et al.  High Mobility Group Box Protein-1 Correlates with Renal Function in Chronic Kidney Disease (CKD) , 2008, Molecular medicine.

[37]  H. Møller,et al.  A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study , 2007, Critical care.

[38]  K. Tracey,et al.  HMGB1 as a late mediator of lethal systemic inflammation. , 2001, American journal of respiratory and critical care medicine.

[39]  K. Tracey,et al.  High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes , 2000, The Journal of experimental medicine.